Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Primary fallopian tube carcinoma - a retrospective analysis of 66 cases
L. Liu1, X. Xu2,†, L. Jia3,†, M. Wei4, B. Qian4, Y. Wu4, Y. Shen4, X. Wang4, H. Pei4, X. Chen4,5,6,*
1 Department of Obstetrics and Gynecology, Sihong People’s Hospital, Sihong
2 Department of Chemotherapy, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu
3 Department of Obstetrics and Gynecology, The Affiliated People’s Hospital of Inner Mongolia Medical College, Inner Mongolia Autonomous Region
4 Department of Gynecologic Oncology, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu
5 State Key Laboratory of Bioelectronics, Southeast University, Nanjing (China)
6 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX (USA)
†These authors contributed equally.
Eur. J. Gynaecol. Oncol. 2015, 36(2), 155–160; https://doi.org/10.12892/ejgo2606.2015
Published: 10 April 2015
Background: Primary fallopian tube carcinoma (PFTC) is a rare malignant gynecologic oncology. There was no consensus on the outcome related clinicopathological characteristics. Present study aims to determine the prognosis associate factors in PFTC. Materials and Methods: In this retrospective study, the authors identified 50 PFTC patients in Jiangsu Institute of Cancer Research and 16 cases in the Affiliated People’s Hospital of Inner Mongolia Medical College between 1988 and 2013. Disease surveillance was conducted based on the follow-up protocol of MD Anderson Cancer Center. Cox proportional hazards model and log-rank test were used to assess the associations between potential clinicpathologic characteristics and the survival durations. Results: The median progression free survival (PFS) and overall survival (OS) of PFTC were 36.9 and 62.7 months, respectively. FIGO Stage (p < 0.01, 0.01), grade (p = 0.02, 0.03), tumor residual after initial debulking surgery (p = 0.05, 0.01), nadir CA-125 (p = 0.01, 0.01) were independently related with PFS and OS. The PFS and OS of patients with Stage II PFTC were similar as those with Stage III-IV (30.7 vs 28.3 and 61.9 vs 49.2 months, respectively) but poorer than those of Stage I cases (N/A). The PFS of patients with paclitaxel-based chemotherapy was longer than those with other regime (51.3 vs 33.1 months), but not OS (62.7 vs 42.6 months). The outcome of patients underwent optimal initial cytoreduction surgery was better than those of suboptimal ones (PFS 56.4 vs 21.2 months and OS 65.3 vs 47.9 months, respectively). Conclusion: PFTC patients with FIGO Stage II disease should be regarded as advanced disease. Paclitaxel based chemotherapy was associated with longer PFS but not OS in PFTC.
Fallopian tube carcinoma